Journal
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 20, Issue 4, Pages 951-960Publisher
WILEY
DOI: 10.1111/jth.15637
Keywords
ADAMTS13 protein; hemolytic anemia; thrombocytopenia; thrombotic microangiopathies; thrombotic thrombocytopenic purpura; von Willebrand factor
Categories
Funding
- ProjektDEAL
Ask authors/readers for more resources
This study analyzed the risks and benefits of an alternate-day dosing regimen of caplacizumab in 25 iTTP patients. The results showed that alternate-day dosing appeared feasible and led to persisting normal platelet counts in most patients. However, some patients experienced exacerbations or relapses that required daily administration of caplacizumab.
Background The anti-von Willebrand factor (VWF) nanobody caplacizumab directly prevents the fatal microthrombi formation in immune-mediated thrombotic thrombocytopenic purpura (iTTP), thereby adding a new therapeutic principle to the treatment of this disorder. However, real-world treatment modalities beyond clinical trials remain heterogeneous. Methods Here, we describe the risks and benefits of an alternate-day dosing regimen for caplacizumab by thoroughly analyzing the timing and outcome of this approach in a retrospective cohort of 25 iTTP patients treated with caplacizumab at seven different medical centers in Austria and Germany between 2018 and 2021. Results Alternate-day dosing of caplacizumab appeared feasible and led to persisting normal platelet counts in most patients. Five patients experienced iTTP exacerbations or relapses that led to the resumption of daily caplacizumab application. VWF activity was repeatedly measured in 16 of 25 patients and documented sufficient suppression by caplacizumab after 24 and 48 h in line with published pharmacodynamics. Conclusion Extension of caplacizumab application intervals from daily to alternate-day dosing may be safely considered in selected patients after 3 to 4 weeks of daily treatment. Earlier modifications may be discussed in low-risk patients but require close monitoring for clinical and laboratory features of thrombotic microangiopathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available